DBV Technologies | DBVT - Selling And Administration Expenses


DBV Technologies reported $3.63M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amarin USD 18.97M 1.03M Dec/2025
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
DBV Technologies USD 3.63M 3.18M Sep/2025
Esperion Therapeutics USD 39.42M 456K Dec/2025
Galectin Therapeutics USD 1.48M 110K Jun/2024
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Insmed USD 212.48M 26.11M Dec/2025
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
United Therapeutics USD 190.6M 38.6M Dec/2025